搜尋結果
Atoltivimab/maftivimab/odesivimab, sold under the brand name Inmazeb, is a fixed-dose combination of three monoclonal antibodies for the treatment of Zaire ebolavirus ( Ebola virus). [2] It contains atoltivimab, maftivimab, and odesivimab-ebgn and was developed by Regeneron Pharmaceuticals. [2]
- Monoclonal antibody
- Inmazeb
- Monoclonal antibody
- Monoclonal antibody
Atoltivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus).
- a" tol tiv' i mab
- Human
- Whole antibody
- Zaire ebolavirus glycoprotein
其他人也問了
What is atoltivimab used for?
What is pemivibart used for?
What are the side effects of odesivimab EBGN?
Is inmazeb an orphan drug?
Odesivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus).
- oh" de siv' i mab
- Human
- Whole antibody
- Zaire ebolavirus glycoprotein
Pemivibart, sold under the brand name Pemgarda, is a monoclonal antibody medication authorized for the pre-exposure prophylaxis (prevention) of COVID‑19. [3] The US Food and Drug Administration (FDA) issued an emergency use authorization for pemivibart in March 2024. [3] [4]
As of August 2023, treatment known as atoltivimab/maftivimab/odesivimab and experimental ansuvimab were found to be 90% effective. [3] [4] [5] [6] In October 2020, the U.S. Food and Drug Administration (FDA) approved atoltivimab/maftivimab/odesivimab with an indication for the treatment of infection caused by Zaire ebolavirus. [7] Overview.
Vilobelimab, sold under the brand name Gohibic, is an investigational medication that is used for the treatment of COVID-19. [1] It is a human-mouse chimeric IgG4 kappa antibody that targets human C5a in plasma. [3]
In October 2020, the U.S. Food and Drug Administration (FDA) approved atoltivimab/maftivimab/odesivimab with an indication for the treatment of infection caused by Zaire ebolavirus. See also
